A comparative study of the diagnostic accuracy of ELISA systems for the detection of anti-neutrophil cytoplasm antibodies available in Japan and Europe

Clinical and Experimental Rheumatology

Volumn 26, Issue 6, 2008, Pages 1027-1033

  Ito Ihara, Toshiko ^a,b,c   Muso, Eri ^a   Kobayashi, Shigeto ^d   Uno, Kazuko ^b   Tamura, Naoto ^e   Yamanishi, Yuji ^f   Fukatsu, Atsushi ^g   Watts, Richard A ^h   Scott, David G I ⁱ   Jayne, David R W ^j   Suzuki, Kazuo ^k,l   Hashimoto, Hiroshi ^e  

^a Kitano Hospital   (Japan)

^b Louis Pasteur Center for Medical Research   (Japan)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d Juntendo University Hospital   (Japan)

^e JUNTENDO UNIVERSITY   (Japan)

^f HIROSHIMA CITY HOSPITAL   (Japan)

^g KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^h IPSWICH HOSPITAL   (United Kingdom)

ⁱ NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^j ADDENBROOKE S HOSPITAL   (United Kingdom)

^k NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^l CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

ANCA associated vasculitides (AAV); Capture ELISA; MPO ANCA; PR3 ANCA; Streptavidin coated ELISA; Systemic vasculitis

Indexed keywords

MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY;

ANTIBODY DETECTION; ARTICLE; BLOOD SAMPLING; CHURG STRAUSS SYNDROME; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; EUROPE; GLOMERULONEPHRITIS; HISTOPATHOLOGY; HUMAN; JAPAN; JAPANESE; MAJOR CLINICAL STUDY; MICROSCOPIC POLYANGIITIS; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SYSTEMIC VASCULITIS; WEGENER GRANULOMATOSIS;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; CHURG-STRAUSS SYNDROME; ENZYME-LINKED IMMUNOSORBENT ASSAY; EUROPE; HUMANS; JAPAN; MYELOBLASTIN; REPRODUCIBILITY OF RESULTS; ROC CURVE; SENSITIVITY AND SPECIFICITY; STREPTAVIDIN; VASCULITIS; WEGENER GRANULOMATOSIS;

EID: 59149105814     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. SAVIGE J, GILLIS D, BENSON E et al.: International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA). Am J Clin Pathol 1999; 111: 507-13.
2. SAVIGE J, DIMECH W, FRITZLER M et al.: Addendum to the International Consensus Statement on testing and reporting of antineutrophil cytoplasmic antibodies. Quality control guidelines, comments, and recommendations for testing in other autoimmune diseases. Am J Clin Pathol 2003; 120: 312-8.
3. HOLLE JU, HELLMICH B, BACKES M et al.: Variations in performance characteristics of commercial enzyme immunoassay kits for detection of antineutrophil cytoplasmic antibodies: What is the optimal cut off? Ann Rheum Dis 2005; 64: 1773-9.
4. LEAVITT RY, FAUCI AS, BLOCH DA et al.: The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 1990; 33: 1101-7.
5. MASI AT, HUNDER GG, LIE JT et al.: The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 1990; 33: 1094-100.
6. JENNETTE JC, FALK RJ, ANDRASSY K et al.: Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37: 187-92.
7. WATTS R, LANE S, HANSLIK T et al.: Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 2007; 66: 222-7.
8. LUQMANI RA, BACON PA, MOOTS RJ et al.: Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 1994; 87: 671-8.
9. HANLEY JA, MCNEIL BJ: The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143: 29-36.
10. HAUGEBERG G, BIE R, BENDVOLD A et al.: Primary vasculitis in a Norwegian community hospital: A retrospective study. Clin Rheumatol 1998; 17: 364-8.
11. WATTS RA, LANE SE, BENTHAM G et al.: Epidemiology of systemic vasculitis: A ten-year study in the United Kingdom. Arthritis Rheum 2000; 43: 414-9.
12. LANE SE, SCOTT DG, HEATON A et al.: Primary renal vasculitis in Norfolk-increasing incidence or increasing recognition? Nephrol Dial Transplant 2000; 15: 23-7.
13. REINHOLD-KELLER E, HERLYN K, WAGNER-BASTMEYER R et al.: Stable incidence of primary systemic vasculitides over five years: Results from German vasculitis register. Arthritis Rheum 2005; 53: 93-9.
14. SAKAI H, KUROKAWA K, KOYAMA A et al.: [Guidelines for the management of rapidly progressive glomerulonephritisc] Nippon Jinzo Gakkai Shi 2002; 44: 55-82.(in Japanese)
15. FUJIMOTO S, UEZONO S, HISANAGA S et al.: Incidence of ANCA-associated primary renal vasculitis in the Miyazaki prefecture: The first population-based retrospective, epidemiologic survey in Japan. Clin J Am Soc Nephrol 2006; 1: 1016-22.
16. GONZALEZ-GAY MA, GARCIA-PORRUA C, GUERRERO J et al.: The epidemiology of the systemic vasculitides in northwest Spain: Implications of the Chapel Hill Consensus Conference Definitions. Arthritis Rheum 2003; 49: 388-93.
17. TIDMAN M, OLANDER R, SVALANDER C et al.: Patients hospitalized because of small vessel vasculitides with renal involvement in the period 1975-1995: Organ involvement, ANCA patterns, seasonal attack rates and fluctuation of annual frequencies. J Intern Med 1998; 244: 133-41.
18. HAUER HA, BAJEMA IM, VAN HOUWELINGEN HC et al.: Renal histology in ANCA-associated vasculitis: Differences between diagnostic and serologic subgroups. Kidney Int 2002; 61: 80-9.
19. FRANSSEN CF, STEGEMAN CA, KALLENBERG CG et al.: Antiproteinase 3- and antimyeloperoxidase-associated vasculitis. Kidney Int. 2000; 57: 2195-206.
20. SPECKS U, WIEGERT EM, HOMBURGER HA: Human mast cells expressing recombinant proteinase 3 (PR3) as substrate for clinical testing for anti-neutrophil cytoplasmic antibodies (ANCA). Clin Exp Immunol 1997; 109: 286-95.
21. LIM LC, TAYLOR JG 3RD, SCHMITZ JL et al.: Diagnostic usefulness of antineutrophil cytoplasmic autoantibody serology. Comparative evaluation of commercial indirect fluorescent antibody kits and enzyme immunoassay kits, Am J Clin Pathol 1999; 111: 363-9.
22. CSERNOK E, AHLQUIST D, ULLRICH S et al.: A critical evaluation of commercial immunoassays for antineutrophil cytoplasmic antibodies directed against proteinase 3 and myeloperoxidase in Wegener's granulomatosis and microscopic polyangiitis. Rheumatology (Oxford) 2002; 41: 1313-7.
23. CSERNOK E, HOLLE J, HELLMICH B et al.: Evaluation of capture ELISA for detection of antineutrophil cytoplasmic antibodies directed against proteinase 3 in Wegener's granulomatosis: First results from a multicentre study. Rheumatology (Oxford) 2004; 43: 174-80.
24. HELLMICH B, CSERNOK E, FREDENHAGEN G et al.: A novel high sensitivity ELISA for detection of antineutrophil cytoplasm antibodies against proteinase-3. Clin Exp Rheumatol 2007; 25: S1-5.
25. TREVISIN M, POLLOCK W, DIMECH W et al.: Antigen-Specific ANCA ELISAs Have Different Sensitivities for Active and Treated Vasculitis and for Nonvasculitic Disease. Am J Clin Pathol 2008; 129: 42-53.
26. HAGEN EC, ANDRASSY K, CHERNOK E et al.: The value of indirect immunofluorescence and solid phase techniques for ANCA detection. A report on the first phase of an international cooperative study on the standardization of ANCA assays. EEC/BCR Group for ANCA Assay Standardization. J Immunol Methods 1993; 159: 1-16.
27. HAGEN EC, ANDRASSY K, CSERNOK E et al.: Development and standardization of solid phase assays for the detection of anti-neutrophil cytoplasmic antibodies (ANCA). A report on the second phase of an international cooperative study on the standardization of ANCA assays. J Immunol Methods 1996; 196: 1-15.
28. HAGEN EC, DAHA MR, HERMANS J et al.: Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. Kidney Int 1998; 53: 743-53.
29. POLLOCK W, DUNSTER K, ROLLAND JM et al.: A comparison of commercial and in-house ELISAs for antineutrophil cytoplasmic antibodies directed against proteinase 3 and myeloperoxidase. Pathology 1999; 31: 38-43.
30. LEE AS, FINKIELMAN JD, PEIKERT T et al.: Agreement of anti-neutrophil cytoplasmic antibody measurements obtained from serum and plasma. Clin Exp Immunol 2006; 146: 15-20.